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Abstract
Aims: To determine whether the additional interventions to standard care are cost-effective in addressing cocaine and
alcohol abuse at 4 months (4 M) and 12 months (12 M) from baseline.
Method: We conducted a cost-effectiveness analysis of a randomized controlled trial with three arms: (1) NIDA’s Standard
intervention (SI); (2) SI plus a Well Woman Exam (WWE); and, (3) SI, WWE, plus four Educational Sessions (4ES).
Results: To obtain an additional cocaine abstainer, WWE compared to SI cost $7,223 at 4 M and $3,611 at 12 M. Per
additional alcohol abstainer, WWE compared to SI cost $3,611 and $7,223 at 4 M and 12 M, respectively. At 12 M, 4ES was
dominated (more costly and less effective) by WWE for abstinence outcomes.
Conclusions: To our knowledge, this is the first cost-effectiveness analysis simultaneously examining cocaine and alcohol
abuse in women. Depending on primary outcomes sought and priorities of policy makers, peer-delivered interventions can
be a cost-effective way to address the needs of this growing, underserved population.
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Introduction
Over 9% of the total US population (23.1 million aged 12 or
older) was in need of treatment for an illicit drug or alcohol use
problem in 2008 [1]. Among females, the percentage of illicit drug
users rose from 5.8% in 2007 to 6.8% in 2010; the number of users
increased from 10.4% to 11.2% over the same period among
males [1,2]. Alcohol and illicit drug use were the third and ninth
leading causes of preventable death in 2000, associated with
85,000 and 17,000 deaths, respectively [3]. Moreover, the
economic costs of drug abuse in the US have increased 5.3%
annually from 1992 to 2002, reaching a total of $180.9 billion, $16
billion of which were health-related [4]. Despite this rise in the
costs of substance abuse, health care spending on substance abuse
only rose 4.1% annually, whereas total health care spending rose
by 6.5%.
A number of behavioral interventions have shown effectiveness
in treating cocaine [5,6] and alcohol abuse [7]. The Women
Teaching Women intervention (WTW) was designed to reduce
substance use and high-risk sexual behaviors through a holistic,
peer-delivered intervention [8]. A randomized, controlled trial
(RCT) examined three arms of WTW: (1) a modified National
Institute on Drug Abuse (NIDA) Cooperative Agreement
Standard Intervention (SI); (2) SI and a field-based Well Woman
Exam (WWE); and (3) SI, WWE, and four Educational Sessions
(4ES). The RCT took place in St. Louis, where, aside from
alcohol, cocaine caused the greatest amount of treatment
admissions in 2007 and remains a major drug problem [9,10].
This study examined ten outcomes related to cocaine and alcohol
use; a companion study analyzed the cost-effectiveness of these
interventions for preventing, STDs and HIV [11]. With cost data
from a previously published [12] micro-costing study of WTW
conducted from the service provider and societal perspectives, we
undertake an incremental cost-effectiveness analysis to determine
the cost per outcome gained for each subsequent arm of the trial.
The literature surrounding cost-effectiveness analyses (CEAs) of
prevention and treatment for cocaine and alcohol abuse continues
to grow [13,14,15]. One article [16] examines the cost-
effectiveness of a screening and brief intervention for alcohol
abuse in a primary care setting. Others [15,17,18,19] address the
additional costs of voucher-based and prize-based contingency
management programs above and beyond standard treatment for
cocaine and opioid dependence. Two CEAs performed analyses
alongside RCTs for alcohol treatment, one comparing social
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behavior and network therapy to motivational enhancement
therapy [20], and another examining combined behavioral and
pharmacotherapies [13]. An additional analysis illustrated the
incremental cost-effectiveness of an enhanced, personalized HIV
intervention compared to SI for preventing drug use [21].
Decision and policy makers need to be aware of interventions’
impact on both cocaine and alcohol abuse because the two
substances are often co-abused. Of the 1,648 cocaine-dependent
patients in the national Drug Abuse Treatment Outcomes Studies
(DATOS), 51% were also alcohol-dependent [22] and in a study
of 158 alcohol-dependent outpatients, 62 of them also manifested
cocaine abuse [23]. This study was conducted in accordance with
the recommendations of the US Panel on Cost-Effectiveness in
Health and Medicine [24].
Methods
The protocol for this study and supporting CONSORT
checklist and flow diagram are available as supporting informa-
tion; see Checklist S1, Protocol S1, and Flow Diagram S1.
Ethics Statement
This study has been approved by IRB Human Studies
Committee at Washington University Hilltop (03-20), Washington
University Medical Center (04-0285) and Yale University Human
Investigation Committee (27312). The randomized controlled trial
in the parent study has been registered with ClinicalTrials.gov and
the registration number is 01235091. Data from the parent study
was analyzed anonymously; written consent was obtained for the
effectiveness data and for the cost data.
Recruitment, Design, and Sample
Community health outreach workers recruited study partici-
pants from targeted recruitment zones, employing street-outreach
methods based on prior work [25]. Eligibility criteria included: (1)
being a woman over the age of 18; (2) reporting sexual activity in
the prior four months; (3) using cocaine, heroin, amphetamines, or
other injection drugs; and (4) residing in the St. Louis metropolitan
area during the study period (2000–2006). Of the 501 women in
the study, 420 participants received the standard intervention (SI)
and completed baseline and both 4-months and 12-months
endpoint assessments. They were randomized to one of three
intervention conditions: SI alone (n = 135); WWE (n = 144); or
4ES (n = 141). Study participants were 90% racial/ethnic
minorities. On average, they were 39 years old, had approximately
11 years of education, and worked for about 7 months when
interviewed at baseline. The number of arrests ranged from an
average of 4.9 for WWE participants to 9.4 for SI.
Intervention Conditions and Costs
Interventions were administered at two community-based
outreach centers shared with the St. Louis City Health
Department. A peer facilitator – a female in drug recovery with
at least one year’s sobriety – conducted the SI, which included: (1)
a 20-minute session for HIV pre-test counseling, blood collection,
and administration of NIDA SI; [26] and (2) two weeks later,
blood test results and HIV post-test counseling. The WWE
intervention included an additional breast and pelvic examination
with cervical cytological testing (Pap smear) provided by a nurse
practitioner, who also obtained a short medical history. 4ES
provided the additional opportunity of attending four educational
sessions delivered by a peer facilitator paired with a health
professional. The interactive sessions (1) were based on the Health
Belief Model; (2) were focused on reducing unhealthy behaviors;
and (3) employed a holistic approach, emphasizing health and
nutrition, stress and coping, substance abuse, and HIV/AIDS.
The intervention costs employed in this analysis are based on a
microcosting methodology, results of which are reported elsewhere
[12].
Effectiveness Measures
For cocaine use, the outcome measures include: occasions used
(number of days used * episodes per day, past 30 days); episodes
per day (past 30 days); cocaine free days (past 30 days); participants
with negative urine tests; proportion of participants abstaining
(past 30 days); and proportion of participants abstaining (past 4
months). For alcohol consumption, we examined the following
outcomes: total drinks (past 7 days); drinks per day of the days
participants drank alcohol (past 7 days); proportion of participants
avoiding heavy drinking (past 7 days; ‘‘heavy drinking’’ defined as
$4 drinks per day on the days participants drank alcohol); [6] and
proportion of participants abstaining (past 30 days).
We estimated incremental effects by a two-step difference-in-
differences approach in order to best compare results across trial
arms. First, we calculated the difference in effectiveness from 4
months to baseline (4 M) and 12 months to baseline (12 M) within
the same intervention. Second, differences within groups were
compared to subsequent interventions to obtain the difference in
differences, or incremental effects. In cases where a smaller mean
from baseline indicates an intervention’s effectiveness, the
incremental effects were calculated to reflect the greater relative
improvement by converting the change to a positive value.
Incremental Cost-Effectiveness Analyses
We estimated the incremental cost-effectiveness of WWE
compared to SI and 4ES compared to WWE by calculating the
ratio of the difference in intervention costs (incremental costs) to
the resulting incremental benefit (incremental effects). This
calculation yields an incremental cost-effectiveness ratio (ICER),
which provides the cost per obtaining an additional unit of
outcome. An intervention is dominated if it is more costly and less
effective than the alternative. Moreover, an intervention is
extended dominated if the alternative is more costly, more
effective and provides a lower ICER [13,27]. An incremental
cost-effectiveness analysis is appropriate in this study because each
subsequent intervention adds significant components.
Sensitivity Analyses
To examine the robustness of our findings and assess sampling
variability, we conducted one- and two-way sensitivity analyses.
One-way sensitivity analyses varied the costs and outcomes
separately. Incremental costs of WWE were examined at $100,
$200, $500 and $1,000 per participant. For 4ES, we evaluated
alternative scenarios and their corresponding costs if: building
rental/utilities decreased by 50% ($549) and 25% ($777); and, if
each session had five people ($759) and three people ($1,233), rather
than four [12]. We varied outcomes through statistically significant
ranges of 5% intervals, determining when an intervention would
become dominated or would no longer be dominated (‘‘switching
point’’), depending on the base case. WWE and 4ES were also
varied to achieve the following clinically significant levels: 12 and 15
occasions of cocaine use (‘‘moderate to high’’ use); [28] 1 and 0.5
episodes of cocaine use per day (an approximate range of
‘‘moderate’’ use); 3 weeks of cocaine abstinence; [29] 85% cocaine
free days (15% days used); [30] and, one and four drink(s) per day on
the days participants drank alcohol (a range for ‘‘sporadic’’ and
‘‘heavy’’ drinkers) [31]. In two-way sensitivity analyses we varied
these parameters simultaneously.
Cost-Effectiveness of Interventions for Abuse
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We constructed acceptability curves as an alternative to
confidence intervals to address uncertainty in the results
[32,33,34]. Selecting randomly with replacement (‘‘bootstrapping’’)
from the base case samples yielded 1,000 new samples. From these
new outcome means, 1,000 ICERs for each outcome measure were
calculated and plotted as a function of willingness to pay (WTP) per
additional abstainer. We analyzed the abstinence results because
they are the most clinically meaningful outcome. The indicator of
cocaine abstainers for the past 30 days provides a better comparison
to alcohol abstainers, for which we only have data for the past 30
days. We chose the comparisons between WWE and SI once it
became clear they provided better ICERs for both outcomes.
Results
Incremental Costs and Effects
Table 1 presents treatment outcomes by treatment arm.
Table 2 reports the mean differences and percentage change in
outcome measures by treatment arm. Each intervention achieved
improvements above pre-treatment levels across all outcomes.
Tables 3 and 4 provide the incremental effects, indicating the
improvements in Table 2 relative to the next least costly
intervention. For cocaine abstainers, greater incremental gains
were generally achieved at 4 M rather than 12 M. For example,
both WWE and 4ES achieved incremental improvements at 4 M
for cocaine abstainers in the past 30 days and past 4 months,
whereas at 12 M only WWE for abstainers in the past 4 months
achieved a positive incremental effect. This trend was not
universal across all outcomes, however. WWE achieved better
outcomes (Table 4) at 12 M than at 4 M for all alcohol outcomes
except abstainers. The incremental costs per participant were $144
and $942 for WWE and 4ES, respectively [12].
Incremental Cost-Effectiveness Analyses: Cocaine
Outcomes
Columns 7–11 of Table 3 report the incremental cost-
effectiveness ratios across all cocaine outcomes at 4 M and 12 M.
Comparing WWE to SI at 4 M, the cost per additional abstainer
(past 30 days) was $14,445, but WWE was dominated by SI at 12 M.
In contrast, at 4 M the ICER for WWE compared to SI of abstainers
in the past 4 months was $7,223, but only $3,611 at 12 M. To obtain
an additional abstainer (past 4 months) at 4 M, WWE compared to
SI cost $11,624 less than 4ES compared to WWE. Furthermore, an
additional abstainer for the past 30 days at 4 M cost $4,401 less for
WWE compared to SI than for 4ES compared to WWE.
The interventions generated lower ICERs, when not dominat-
ed, for additional occasion averted, episode reduced per day, and
cocaine free day than for the abstinence outcomes. Moreover, 4ES
compared to WWE had lower ICERs for the non-abstinence
outcomes at 12 M than at 4 M.
Incremental Cost-Effectiveness Analyses: Alcohol
Outcomes
Columns 6–9 of Table 4 report the incremental cost-
effectiveness ratios across all alcohol outcomes at 4 M and
Table 1. Effectiveness Measures by Treatment Group.
SI WWE 4ES
(n =135) (n =144) (n=141)
Treatment Outcome Mean (s.d.) Mean (s.d.) Mean (s.d.)
Cocaine Use
Occasionsa Used, past 30 daysb
Pre-treatment 48.91 (96.2) 54.51 (104.9) 60.84 (144.1)
End of treatment, 4 mo 19.04 (41.2) 24.70 (69.6) 24.59 (63.3)
End of treatment, 12 mo 29.46 (62.6) 34.63 (71.8) 19.08 (38.7)
Episodes per Day, past 30 daysb
Pre-treatment 3.02 (3.8) 3.22 (3.8) 3.46 (5.7)
End of treatment, 4 mo 2.04 (3.3) 1.95 (3.2) 1.92 (3.6)
End of treatment, 12 mo 2.29 (4.9) 2.56 (5.2) 1.91 (2.7)
Cocaine Free Days, past 30 days
Pre-treatment 19.21 (10.9) 19.33 (11.6) 19.66 (11.0)
End of treatment, 4 mo 25.03 (7.4) 24.97 (8.3) 24.63 (9.1)
End of treatment, 12 mo 22.31 (9.7) 22.06 (10.1) 24.26 (7.9)
Participants with Negative Urine Testsc
Pre-treatment 21 19 14
End of treatment, 12 mo 34 32 26
Abstaining,d past 30 days
Pre-treatment 0.13 (0.3) 0.13 (0.3) 0.14 (0.4)
End of treatment, 4 mo 0.43 (0.5) 0.44 (0.5) 0.50 (0.5)
End of treatment, 12 mo 0.33 (0.5) 0.33 (0.5) 0.32 (0.5)
Abstaining,d past 4 months
Pre-treatment 0.07 (0.3) 0.06 (0.2) 0.08 (0.3)
End of treatment, 4 mo 0.33 (0.5) 0.34 (0.5) 0.41 (0.5)
End of treatment, 12 mo 0.28 (0.5) 0.31 (0.5) 0.30 (0.5)
Alcohol Consumption
Total Drinks, past 7 daysb
Pre-treatment 19.26 (31.5) 22.02 (40.8) 22.41 (46.3)
End of treatment, 4 mo 11.75 (23.0) 15.66 (34.6) 12.00 (28.5)
End of treatment, 12 mo 16.40 (27.8) 14.01 (24.6) 13.03 (23.0)
Drinks per Day,e past 7 daysb
Pre-treatment 4.55 (5.9) 5.07 (7.5) 5.38 (7.9)
End of treatment, 4 mo 3.01 (4.8) 4.42 (8.2) 3.18 (5.2)
End of treatment, 12 mo 4.30 (7.3) 3.84 (5.4) 3.41 (4.9)
Preventing Heavy Drinkers,f past 7 daysb
Pre-treatment 0.59 (0.49) 0.59 (0.49) 0.57 (0.50)
End of treatment, 4 mo 0.69 (0.46) 0.66 (0.47) 0.67 (0.47)
End of treatment, 12 mo 0.60 (0.49) 0.63 (0.48) 0.62 (0.49)
Abstaining,g past 30 daysb
Pre-treatment 0.28 (0.45) 0.24 (0.43) 0.30 (0.46)
End of treatment, 4 mo 0.41 (0.49) 0.41 (0.49) 0.41 (0.49)
End of treatment, 12 mo 0.37 (0.49) 0.35 (0.48) 0.39 (0.49)
Abbreviations: SI, NIDA’s Standard Intervention; WWE, SI plus Well Woman
Exam; 4ES, SI, WWE plus four educational sessions.
aOccasions = days used * times per day.
bMissing data from 1–2 patients at some endpoints.
cMeasured only at BL and 12 mo. The endpoint sample for each intervention
included 121, 129 and 129 participants, respectively. Standard deviation not
applicable here because value is number of participants.
dProportion of participants abstaining from cocaine.
eNumber of drinks per day, of the days participants drank alcohol.
fProportion of participants avoiding heavy drinking. ‘‘Heavy drinking’’ defined
as $4 drinks per day of the days participants drank alcohol.
gProportion of participants abstaining from alcohol.
doi:10.1371/journal.pone.0033594.t001
Table 1. Cont.
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12 M. For cost per abstainer, WWE was cost-effective compared
to SI, with an ICER of $3,611 at 4 M and $7,223 at 12 M,
whereas WWE dominated 4ES at both 4 M and 12 M.
Conversely, WWE was dominated by SI at 4 M for all other
alcohol outcomes (drinks, drinks per day, and heavy drinkers
prevented).
At 4 M, 4ES compared to WWE cost $233 and $608 to avoid
an additional drink and to reduce an additional drink per day,
respectively. Moreover, an additional heavy drinker was prevented
by 4ES compared to WWE at a cost of $31,410.
At 12 M, only 4ES compared to WWE for the cost per
abstainer was dominated. The cost per heavy drinker prevented
for 4ES compared to WWE provided the largest ICER ($94,230).
The smallest ICER was the cost per additional drink avoided
comparing WWE to SI ($28), whereas comparing 4ES to WWE on
the same outcome yielded an ICER of $688. WWE compared to
SI cost $4,815 to prevent an additional heavy drinker. For the cost
per reduced drink per day, ICERs were $147 for WWE compared
to SI and $1,273 for 4ES compared to WWE.
Sensitivity Analyses
One-way sensitivity analyses. Varying the costs per
participant changed the ICERs proportionally (Table S1). At
4 M, for cocaine abstainers (past 4 months), the ICER for WWE
compared to SI ranged from $5,000 to $50,000 (base case ICER:
$7,223) at $100 to $1,000 per participant, whereas comparing 4ES
to WWE at costs that varied from $549 to $1,233 yielded ICERs
from $10,980 to $24,660 (base case: $18,846). At 4 M, for alcohol
abstainers, WWE ranged from $2,500 to $25,000 (base case:
$3,611) at $100 to $1,000 per participant and at 12 M the
equivalent cost changes yielded an ICER range of $5,000 to
$50,000 (base case: $7,223). For WWE at incremental costs of
$500 or $1,000 (base case: $144.45), excluding dominated options,
only cocaine abstainers in the past 30 days at 4 M yielded ICERs
above $50,000. Generating the smallest ICERs, the cost per
cocaine occasion averted for 4ES at 12 M varied from $25 to $56.
Varying the effectiveness parameters across statistically
(Table 5) and clinically significant ranges (Table 6) indicated
the sensitivity of each finding. Some outcomes required greater
changes than others to achieve a switching point. For example,
4ES required a 115% effectiveness decrease at 12 M and a 30%
decrease at 4 M in reducing occasions of cocaine use and a 50%
decrease at 12 M and a 15% decrease at 4 M in reducing an
episode of cocaine use per day to become dominated by WWE. If
WWE obtained 10% fewer cocaine abstainers (past 4 months), it
was dominated by SI at 4 M but was still cost-effective at 12 M
($16,050; Table S2) and did not become dominated by SI until its
effectiveness was decreased by 15%. Moreover, 4ES remained
cost-effective in reducing a drink per day at 4 M up to the point at
which its effectiveness decreased by 50%, while WWE at 4 M
required a 25% increase in effectiveness to eliminate SI
domination.
Conversely, an increase or decrease of as low as 5% revealed a
switching point for other cocaine and alcohol outcomes. For
example, WWE was dominated by SI at 4 M and 12 M for
cocaine free days in the base case; however, a 5% increase in
Table 2. Mean Differences and Percent Change by Treatment Group at 4 and 12 Monthsa.
4 months 12 months
Treatment Outcome SI WWE 4ES SI WWE 4ES
Cocaine Use
Occasions Usedb 229.87 (261.1%) 229.81 (254.7%) 236.25 (259.6%) 219.45 (239.8%) 219.88 (236.5%) 241.76 (268.6%)
Episodes per Dayc 20.98 (232.5%) 21.27 (239.4%) 21.54 (244.5%) 20.73 (224.2%) 20.66 (220.5%) 21.55 (244.8%)
Days Freed 5.82 (30.3%) 5.64 (29.2%) 4.97 (25.3%) 3.10 (16.1%) 2.73 (14.1%) 4.60 (23.4%)
Negative Urine Testse N/A N/A N/A 13.00 (61.9%) 13.00 (68.4%) 12.00 (85.7%)
Abstaining, past 30 daysf 0.30 (231%) 0.31 (238%) 0.36 (257%) 0.20 (154%) 0.20 (154%) 0.18 (129%)
Abstaining, past 4 mog 0.26 (371%) 0.28 (467%) 0.33 (413%) 0.21 (300%) 0.25 (417%) 0.22 (275%)
Alcohol Consumption
Total Drinksh 27.51 (239%) 26.36 (228.9%) 210.41 (246.5%) 22.86 (214.8%) 28.01 (236.4%) 29.38 (241.9%)
Drinks per Dayi 21.54 (233.8%) 20.65 (212.8%) 22.20 (240.9%) 20.25 (25.5%) 21.23 (224.3%) 21.97 (236.6%)
Preventing Heavy
Drinkersj
0.10 (16.9%) 0.07 (11.9%) 0.10 (17.5%) 0.01 (1.7%) 0.04 (6.8%) 0.05 (8.8%)
Abstainingk 0.13 (46.4%) 0.17 (70.8%) 0.11 (36.7%) 0.09 (32.1%) 0.11 (45.8%) 0.09 (30.0%)
Abbreviations: SI, NIDA’s Standard Intervention; WWE, SI plus Well Woman Exam; 4ES, SI, WWE plus four educational sessions.
aValues represent differences and percentage change (parentheses) within groups from baseline. Due to rounding, calculations may not exactly reflect data from
Table 1.
bNumber of occasions used cocaine (number of days used * times per day); negative number indicates improvement.
cNumber of episodes used cocaine per day; negative number indicates improvement.
dNumber of days free from cocaine; positive number indicates improvement.
eNumber of negative urine tests; positive number indicates improvement. We examined baseline and incremental data, but did not perform an incremental cost-
effectiveness analysis on this outcome due to missing data.
fProportion of participants abstaining from cocaine, past 30 days; positive number indicates improvement.
gProportion of participants abstaining from cocaine, past 4 months; positive number indicates improvement.
hTotal number of alcoholic drinks, past 7 days; negative number indicates improvement.
iMean number of alcoholic drinks per day, of the days participants drank alcohol, past 7 days; negative number indicates improvement.
jProportion of participants avoiding heavy drinking, past 7 days; ‘‘Heavy drinking’’ defined as $4 drinks per day of the days participants drank alcohol; positive number
indicates improvement.
kProportion of participants abstaining from alcohol, past 30 days; positive number indicates improvement.
doi:10.1371/journal.pone.0033594.t002
Cost-Effectiveness of Interventions for Abuse
PLoS ONE | www.plosone.org 4 March 2012 | Volume 7 | Issue 3 | e33594
T
a
b
le
3
.
In
cr
e
m
e
n
ta
l
C
o
st
-E
ff
e
ct
iv
e
n
e
ss
A
n
al
ys
e
s:
C
o
ca
in
e
O
u
tc
o
m
e
sa
.
In
cr
e
m
e
n
ta
l
C
o
st
s
In
cr
e
m
e
n
ta
l
E
ff
e
ct
sb
IC
E
R
(D
C
/D
E
,
$)
D
C
o
st
s
p
e
r
p
a
rt
ic
ip
a
n
t
O
cc
a
si
o
n
s
U
se
d
c
E
p
is
o
d
e
s
p
e
r
D
a
y
d
D
a
y
s
F
re
e
e
A
b
st
a
in
in
g
,
p
a
st
3
0
d
a
y
sf
A
b
st
a
in
in
g
,
p
a
st
4
m
o
n
th
sg
C
o
st
p
e
r
O
cc
a
si
o
n
A
v
e
rt
e
d
h
C
o
st
p
e
r
E
p
is
o
d
e
R
e
d
u
ce
d
i
C
o
st
p
e
r
C
o
ca
in
e
F
re
e
D
a
y
h
C
o
st
p
e
r
A
b
st
a
in
e
r,
p
a
st
3
0
d
a
y
s
C
o
st
p
e
r
A
b
st
a
in
e
r,
p
a
st
4
m
o
n
th
s
T
re
a
tm
e
n
t
G
ro
u
p
s
B
L
to
4
m
o
SI
--
--
--
--
--
--
--
--
--
--
--
SI
+W
W
E
$1
4
4
.4
5
2
0
.0
6
0
.2
9
2
0
.1
8
0
.0
1
0
.0
2
D
$4
9
8
.1
0
D
$1
4
,4
4
5
.0
0
$7
,2
2
2
.5
0
SI
+W
W
E+
4
ES
$9
4
2
.3
0
6
.4
4
0
.2
7
2
0
.6
7
0
.0
5
0
.0
5
$1
4
6
.3
2
$3
,4
9
0
.0
0
D
$1
8
,8
4
6
.0
0
$1
8
,8
4
6
.0
0
B
L
to
1
2
m
o
SI
--
--
--
--
--
--
--
--
--
--
--
SI
+W
W
E
$1
4
4
.4
5
0
.4
3
2
0
.0
7
2
0
.3
7
0
0
.0
4
ED
D
D
D
$3
,6
1
1
.2
5
SI
+W
W
E+
4
ES
$9
4
2
.3
0
2
1
.8
8
0
.8
9
1
.8
7
2
0
.0
2
2
0
.0
3
$4
3
.0
7
$1
,0
5
8
.7
6
$5
0
3
.9
0
D
D
A
b
b
re
vi
at
io
n
s:
SI
,
N
ID
A
’s
St
an
d
ar
d
In
te
rv
e
n
ti
o
n
;
W
W
E,
SI
p
lu
s
W
e
ll
W
o
m
an
Ex
am
;
4
ES
,
SI
,
W
W
E
p
lu
s
fo
u
r
e
d
u
ca
ti
o
n
al
se
ss
io
n
s;
IC
ER
,
in
cr
e
m
e
n
ta
l
co
st
e
ff
e
ct
iv
e
n
e
ss
ra
ti
o
,
w
h
ic
h
is
th
e
d
if
fe
re
n
ce
in
co
st
d
iv
id
e
d
b
y
th
e
d
if
fe
re
n
ce
in
e
ff
e
ct
iv
e
n
e
ss
as
co
m
p
ar
e
d
w
it
h
th
e
n
e
xt
le
as
t
co
st
ly
in
te
rv
e
n
ti
o
n
,
an
d
in
d
ic
at
e
s
co
st
p
e
r
ad
d
it
io
n
al
o
u
tc
o
m
e
ac
h
ie
ve
d
;
B
L,
b
as
e
lin
e
;
D
,
d
o
m
in
at
e
d
,
w
h
ic
h
in
d
ic
at
e
s
th
at
th
e
in
te
rv
e
n
ti
o
n
is
m
o
re
co
st
ly
an
d
le
ss
e
ff
e
ct
iv
e
th
an
th
e
al
te
rn
at
iv
e
;
ED
,
e
xt
e
n
d
e
d
d
o
m
in
at
e
d
,
w
h
ic
h
in
d
ic
at
e
s
th
at
th
e
n
e
xt
al
te
rn
at
iv
e
is
m
o
re
co
st
ly
,
m
o
re
e
ff
e
ct
iv
e
an
d
h
as
a
b
e
tt
e
r
IC
ER
.
a
C
o
st
s
fr
o
m
R
u
g
e
r
e
t
al
.,
2
0
1
0
.
D
u
e
to
ro
u
n
d
in
g
,
ca
lc
u
la
ti
o
n
s
m
ay
n
o
t
e
xa
ct
ly
re
fl
e
ct
d
at
a
fr
o
m
T
ab
le
2
.
IC
ER
s
d
id
n
o
t
n
e
e
d
to
b
e
ad
ju
st
e
d
b
e
ca
u
se
th
e
in
te
rv
e
n
ti
o
n
h
as
a
su
ff
ic
ie
n
tl
y
lo
n
g
fo
llo
w
u
p
ti
m
e
p
e
ri
o
d
.
b
P
o
si
ti
ve
n
u
m
b
e
r
in
d
ic
at
e
s
in
cr
e
m
e
n
ta
l
im
p
ro
ve
m
e
n
t.
Ea
ch
va
lu
e
is
th
e
d
if
fe
re
n
ce
o
f
th
e
d
if
fe
re
n
ce
s
fr
o
m
T
ab
le
2
.
c
N
u
m
b
e
r
o
f
o
cc
as
io
n
s
u
se
d
co
ca
in
e
,
p
as
t
3
0
d
ay
s
(n
u
m
b
e
r
o
f
d
ay
s
u
se
d
*
ti
m
e
s
p
e
r
d
ay
).
d
N
u
m
b
e
r
o
f
e
p
is
o
d
e
s
u
se
d
co
ca
in
e
p
e
r
d
ay
,
p
as
t
3
0
d
ay
s.
e
N
u
m
b
e
r
o
f
co
ca
in
e
fr
e
e
d
ay
s,
p
as
t
3
0
d
ay
s.
f P
ro
p
o
rt
io
n
o
f
p
ar
ti
ci
p
an
ts
ab
st
ai
n
in
g
fr
o
m
co
ca
in
e
,
p
as
t
3
0
d
ay
s.
g
P
ro
p
o
rt
io
n
o
f
p
ar
ti
ci
p
an
ts
ab
st
ai
n
in
g
fr
o
m
co
ca
in
e
,
p
as
t
4
m
o
n
th
s.
h
P
as
t
3
0
d
ay
s.
i P
e
r
d
ay
,
p
as
t
3
0
d
ay
s.
d
o
i:1
0
.1
3
7
1
/j
o
u
rn
al
.p
o
n
e
.0
0
3
3
5
9
4
.t
0
0
3
Cost-Effectiveness of Interventions for Abuse
PLoS ONE | www.plosone.org 5 March 2012 | Volume 7 | Issue 3 | e33594
T
a
b
le
4
.
In
cr
e
m
e
n
ta
l
C
o
st
-E
ff
e
ct
iv
e
n
e
ss
A
n
al
ys
e
s:
A
lc
o
h
o
l
O
u
tc
o
m
e
sa
.
In
cr
e
m
e
n
ta
l
C
o
st
s
In
cr
e
m
e
n
ta
l
E
ff
e
ct
sb
IC
E
R
(D
C
/D
E
,
$)
D
C
o
st
s
p
e
r
p
a
rt
ic
ip
a
n
t
T
o
ta
l
D
ri
n
k
sc
D
ri
n
k
s
p
e
r
D
a
y
d
P
re
v
e
n
ti
n
g
H
e
a
v
y
D
ri
n
k
e
rs
e
A
b
st
a
in
in
g
f
C
o
st
p
e
r
D
ri
n
k
A
v
o
id
e
d
g
C
o
st
p
e
r
R
e
d
u
ce
d
D
ri
n
k
p
e
r
D
a
y
g
C
o
st
p
e
r
H
e
a
v
y
D
ri
n
k
e
r
P
re
v
e
n
te
d
h
C
o
st
p
e
r
A
b
st
a
in
e
ri
T
re
a
tm
e
n
t
G
ro
u
p
s
B
L
to
4
m
o
SI
--
--
--
--
--
--
--
--
--
SI
+W
W
E
$1
4
4
.4
5
2
1
.1
5
2
0
.8
9
2
0
.0
3
0
.0
4
D
D
D
$3
,6
1
1
.3
5
SI
+W
W
E
+4
ES
$9
4
2
.3
0
4
.0
5
1
.5
5
0
.0
3
2
0
.0
6
$2
3
2
.6
7
$6
0
7
.9
4
$3
1
,4
1
0
.0
0
D
B
L
to
1
2
m
o
SI
--
--
--
--
--
--
--
--
--
SI
+W
W
E
$1
4
4
.4
5
5
.1
5
0
.9
8
0
.0
3
0
.0
2
$2
8
.0
5
$1
4
7
.4
0
$4
,8
1
5
.0
0
$7
,2
2
2
.5
0
SI
+W
W
E
+4
ES
$9
4
2
.3
0
1
.3
7
0
.7
4
0
.0
1
2
0
.0
2
$6
8
7
.8
1
$1
,2
7
3
.3
8
$9
4
,2
3
0
.0
0
D
A
b
b
re
vi
at
io
n
s:
SI
,
N
ID
A
’s
St
an
d
ar
d
In
te
rv
e
n
ti
o
n
;
W
W
E,
SI
p
lu
s
W
e
ll
W
o
m
an
Ex
am
;
4
ES
,
SI
,
W
W
E
p
lu
s
fo
u
r
e
d
u
ca
ti
o
n
al
se
ss
io
n
s;
IC
ER
,
in
cr
e
m
e
n
ta
l
co
st
e
ff
e
ct
iv
e
n
e
ss
ra
ti
o
,
w
h
ic
h
is
th
e
d
if
fe
re
n
ce
in
co
st
d
iv
id
e
d
b
y
th
e
d
if
fe
re
n
ce
in
e
ff
e
ct
iv
e
n
e
ss
as
co
m
p
ar
e
d
w
it
h
th
e
n
e
xt
le
as
t
co
st
ly
in
te
rv
e
n
ti
o
n
,
an
d
in
d
ic
at
e
s
co
st
p
e
r
ad
d
it
io
n
al
o
u
tc
o
m
e
ac
h
ie
ve
d
;
B
L,
b
as
e
lin
e
;
D
,
d
o
m
in
at
e
d
,
w
h
ic
h
in
d
ic
at
e
s
th
at
th
e
in
te
rv
e
n
ti
o
n
is
m
o
re
co
st
ly
an
d
le
ss
e
ff
e
ct
iv
e
th
an
th
e
al
te
rn
at
iv
e
.
a
C
o
st
s
fr
o
m
R
u
g
e
r
e
t
al
.,
2
0
1
0
.
D
u
e
to
ro
u
n
d
in
g
,
ca
lc
u
la
ti
o
n
s
m
ay
n
o
t
e
xa
ct
ly
re
fl
e
ct
d
at
a
fr
o
m
T
ab
le
2
.
IC
ER
s
d
id
n
o
t
n
e
e
d
to
b
e
ad
ju
st
e
d
b
e
ca
u
se
th
e
in
te
rv
e
n
ti
o
n
h
as
a
su
ff
ic
ie
n
tl
y
lo
n
g
fo
llo
w
u
p
ti
m
e
p
e
ri
o
d
.
b
P
o
si
ti
ve
n
u
m
b
e
r
in
d
ic
at
e
s
in
cr
e
m
e
n
ta
l
im
p
ro
ve
m
e
n
t.
Ea
ch
va
lu
e
is
th
e
d
if
fe
re
n
ce
o
f
th
e
d
if
fe
re
n
ce
s
fr
o
m
T
ab
le
2
.
c
T
o
ta
l
n
u
m
b
e
r
o
f
al
co
h
o
lic
d
ri
n
ks
,
p
as
t
7
d
ay
s.
d
M
e
an
n
u
m
b
e
r
o
f
al
co
h
o
lic
d
ri
n
ks
p
e
r
d
ay
,
o
f
th
e
d
ay
s
p
ar
ti
ci
p
an
ts
d
ra
n
k
al
co
h
o
l,
p
as
t
7
d
ay
s.
e
P
ro
p
o
rt
io
n
o
f
p
ar
ti
ci
p
an
ts
av
o
id
in
g
h
e
av
y
d
ri
n
ki
n
g
,
p
as
t
7
d
ay
s.
‘‘H
e
av
y
d
ri
n
ki
n
g
’’
d
e
fi
n
e
d
as
$
4
d
ri
n
ks
p
e
r
d
ay
o
f
th
e
d
ay
s
p
ar
ti
ci
p
an
ts
d
ra
n
k
al
co
h
o
l.
f P
ro
p
o
rt
io
n
o
f
p
ar
ti
ci
p
an
ts
ab
st
ai
n
in
g
fr
o
m
al
co
h
o
l,
p
as
t
3
0
d
ay
s.
g
P
as
t
7
d
ay
s.
h
P
as
t
7
d
ay
s.
‘‘H
e
av
y
d
ri
n
ke
r’
’
in
cl
u
d
e
s
p
ar
ti
ci
p
an
ts
w
h
o
d
ri
n
k
$
4
d
ri
n
ks
p
e
r
d
ay
o
f
th
e
d
ay
s
p
ar
ti
ci
p
an
ts
d
ra
n
k
al
co
h
o
l.
i P
as
t
3
0
d
ay
s.
d
o
i:1
0
.1
3
7
1
/j
o
u
rn
al
.p
o
n
e
.0
0
3
3
5
9
4
.t
0
0
4
Cost-Effectiveness of Interventions for Abuse
PLoS ONE | www.plosone.org 6 March 2012 | Volume 7 | Issue 3 | e33594
effectiveness for WWE eliminated domination and yielded an
ICER of $135 at 4 M and $197 at 12 M.
Two-way sensitivity analyses. We also determined the
impact of more than one factor on results (Table S3).
For the cost per additional cocaine abstainer (past 30 days),4ES
at 4 M yielded ICERs ranging from $5,490 to $12,330 at
incremental costs of $549 to $1,233 per participant and a 10%
increase in effectiveness. For cocaine free days, a 5% increase in
effectiveness and cost range of $100 to $1,000 per participant for
WWE compared to SI yielded an ICER range of $94 to $936 at
4 M and $136 to $1,364 at 12 M (base case: dominated). For
alcohol outcomes, relative to SI, WWE would cost $51,282 per
additional alcohol abstainer at 4 M if the effectiveness of WWE
decreased by 5% and incremental costs increased to $1,000 per
participant.
Threshold Analyses. Figure 1 illustrates changes in ICERs
relative to changes in costs and effectiveness in a stepwise fashion.
For cocaine episodes per day, WWE was dominated by SI with a
15% decrease in effectiveness for WWE, but yielded an ICER
under $2,000 with an incremental cost of $100 and decrease in
effectiveness of 10%. At incremental costs of $500, WWE was cost-
effective compared to SI at as large a decrease as 10% in
effectiveness, yielded an ICER under $2,000 at base case
effectiveness, and under $500 if WWE achieved a mean of 1
Table 5. One-Way Sensitivity Analyses of Switching Points: Outcomes.
ICER (DC/DE, $), 4 mo ICER (DC/DE, $), 12 mo
Parameter Varieda B-A C-B B-A C-B
Cocaine Use
Occasionsb Used, past 30 days +5% ($123) 230% 25% 2115%
Episodes per Day, past 30 days 215% 215% +5% ($2,491) 250%
Cocaine Free Days, past 30 days +5% ($135) +5% ($1,678) +5% ($197) 210%
Abstaining, past 30 days 25% 210% +5% ($8,755) +10% ($78,525)
Abstaining, past 4 months 210% 215% 215% +15% ($62,820)
Alcohol Consumption
Total Drinks, past 7 days +10% ($347) 235% 240% 215%
Drinks per Day, past 7 days +25% ($672) 250% 230% 225%
Preventing Heavy Drinkers,c past 7 days +5% ($48,150) 25% 25% 25%
Abstaining, past 30 days 210% +15% ($628,200) 210% +10% ($49,595)
Abbreviations: ICER, incremental cost effectiveness ratio, which is the difference in cost divided by the difference in effectiveness as compared with the next least costly
intervention and indicates cost per additional outcome achieved; A, SI intervention; B, WWE intervention; C, 4ES intervention.
Table S2 includes complete results of ICERs at 5% increments en route to the switching points.
aPercentage varied indicates percentage change of base case value for more costly alternative only, whereas base case of its comparator remain the same. A negative
percentage change indicates less effective intervention than the base case, which may or may not indicate a mean lower than the base case (see Table 2). A positive
percentage change indicates a more effective intervention than base case. Included in parentheses is the corresponding ICER.
bOccasions = days used * times per day.
c‘‘Heavy drinker’’ includes participants who drink $4 drinks per day of the days participants drank alcohol.
doi:10.1371/journal.pone.0033594.t005
Table 6. One-Way Sensitivity Analyses of Clinically Significant Outcomes.
ICER (DC/DE, $), 4 mo ICER (DC/DE, $), 12 mo
Parameter Varieda B-A C-B B-A C-B
Cocaine Use
Occasionsb Used, past 30 days - 12 $11 $50 $6 $33
Occasionsb Used, past 30 days - 15 $15 $59 $7 $36
Episodes per Day, past 30 days - 1 $116 $792 $97 $524
Episodes per Day, past 30 days - 0.5 $83 $558 $73 $410
Cocaine Free Days, past 30 days - 3 weeks $51 $349 $26 $168
Cocaine Free Days, past 30 days - 85% free $413 $4,712 $47 $303
Alcohol Consumption
Drinks per Day, past 7 days - 4 D $1,291 $176 $6,282
Drinks per Day, past 7 days - 1 $57 $253 $38 $299
Abbreviations: ICER, incremental cost effectiveness ratio, which is the difference in cost divided by the difference in effectiveness as compared with the next least costly
intervention and indicates cost per additional outcome achieved; A, SI intervention; B, WWE intervention; C, 4ES intervention.
aIndicates the outcome achieved in the analysis.
bOccasions = days used * times per day.
doi:10.1371/journal.pone.0033594.t006
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episode per day. 4ES proved highly sensitive for preventing heavy
drinkers with an ICER under $25,000 across all costs with a 5%
increase in effectiveness.
Acceptability Curves. Figure 2 portrays acceptability
curves that address the uncertainty of the results, indicating the
probability that WWE is cost-effective when compared to SI at a
variety of willingness to pay (WTP) values. For example, the WWE
intervention has a 0.5 probability of being cost-effective if society’s
WTP is $20,000 per additional cocaine abstainer (past 30 days) or
$2,600 per additional alcohol abstainer. If the WTP is $25,000, it
has a roughly 0.72 probability of being cost-effective for alcohol
abstainers. Figure 3 presents willingness to pay depending on
intervention costs and changes in intervention effectiveness in
achieving per additional cocaine abstainer and alcohol abstainer.
For example, a 5% increase in effectiveness for 4ES (at a cost of
$549) relative to WWE and for WWE (at a cost of $500) relative to
SI yields a willingness to pay of less than $10,000 per additional
cocaine abstainer and per additional alcohol abstainer,
respectively.
Discussion
To our knowledge, this is the first cost-effectiveness analysis
simultaneously examining cocaine and alcohol abuse in women.
The outcome of preventing heavy drinkers proved highly sensitive
to changes in effectiveness values. Moreover, the magnitude of an
ICER in the base case did not always predict its sensitivity.
Decreasing the effectiveness of WWE for alcohol abstainers by 5%
and varying the costs from $100 to $1,000 yielded significantly
different ICER ranges at 4 M ($5,128–$51,282) and at 12 M
($40,000–$400,000), despite comparable base case ICERs ($3,611
at 4 M and $7,223 at 12 M). In cases of dominance among
cocaine outcomes, the sensitivity to switching points varied
considerably. It took only a small improvement (5%) in cocaine
abstainers (past 30 days) at 12 M for WWE compared to SI to
achieve a low ICER ($8,755); yet the same percentage improve-
ment for 4ES failed to eliminate domination by WWE, and
doubling that improvement led to a significantly higher ICER
($78,525). Although SI dominated WWE in the base case for
cocaine free days, increasing effectiveness of WWE by 5% and
varying incremental costs from $100 to $1,000 yielded low ICERs
ranging from $94 to $936 at 4 M and $136 to $1,364 at 12 M.
Our results yielded ICERs that compare favorably to those in
the literature, although one needs to be cautious in comparing
results across different studies. CEAs alongside randomized
controlled trials that examine the cost per obtaining an additional
cocaine or alcohol abstainer, aside from analyses of contingency
management (CM) programs, are scarce if not non-existent. We
identified one study that examined costs and treatment readmis-
sion rates [35] and one that looked at costs per abstainer from
substance abuse [36], both drawing on calculated ratios of the cost
per probability of success. Other studies examined the incremental
cost of extending drug abstinence. To extend the longest duration
of cocaine and opioid abstinence by an additional week, Olmstead
and Petry [15] report costs of $212 and $166 for voucher-based
and prize-based CM interventions, respectively, compared to
standard outpatient treatment. To reduce an additional day of
drug use among out-of-treatment substance abusers at risk for
HIV, Zarkin et al. [21] measured ICERs ranging from $36 to $140
for an enhanced intervention compared to SI. Schumacher et al.
[37] estimated costs of two addiction interventions compared to
usual care to be $1,007 and $1,244 for an additional week of drug
abstinence among homeless persons. For non-abstinence out-
comes, Zarkin et al. [13] determined that medical management
combined with either naltrexone or naltrexone and acamprosate
was cost-effective in avoiding heavy drinking (using the same
heavy drinking definition as ours), with ICERs of $2,847 and
$8,095. Jofre-Bonet et al. [38] examined the cost-effectiveness of
Figure 1. Two-way Sensitivity Analyses on Cost and Effectiveness.
doi:10.1371/journal.pone.0033594.g001
Figure 2. Acceptability Curves.
doi:10.1371/journal.pone.0033594.g002
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disulfiram in addition to methadone maintenance for treating
cocaine dependence, yielding an incremental cost of $73 per day
of cocaine reduced.
The cost-effectiveness literature on substance abuse contains
comparable analyses for treating heroin abuse, where: 7-day
abstinence costs under AUD$4,000 (US$2,520) per additional
patient for three detoxification methods compared to conventional
outpatient treatment, the latter of which was also dominated by
buprenorphine; [39] in prison, methadone treatment compared to
no treatment costs AUD$38 (US$22) per additional heroin free
day; [40] buprenorphine was dominated by methadone mainte-
nance for obtaining an additional heroin free day [41]. The cost to
prevent a recent quitter from smoking (relapse prevented) among
low-income pregnant women was $1,217 [42].
As a benchmark of comparison for determining the worth of a
QALY for alcohol treatment in the UK, two studies [14,20] noted
a range consistent with National Institute of Clinical Excellence
(NICE) valuation of £20,000–30,000 ($37,768–56,652) per QALY
gained. Additional studies reported the total benefits gained by
society, determining the cost-effectiveness of: alcohol prevention
[43] and a screening and brief intervention for excessive alcohol
use in a primary care setting [16] in terms of QALYs; and
Figure 3. Willingness to Pay per Abstainer.
doi:10.1371/journal.pone.0033594.g003
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acamprosate therapy in terms of cost savings per additional
abstinent alcoholic [44].
We urge caution, however, not only in comparing our results to
QALYs, but also in using QALYs as a measure for substance
abuse prevention and treatment in an overarching social utility
exercise (e.g. league table) because they overlook broader societal
benefits and concerns [45]. As a single quantitative scale, QALYs
assign less weight to the disabled and elderly in health care
rationing and introduce problems of incommensurability [46,47].
Moreover, since incremental CEAs yield ICERs that are reflective
of their comparators, a low ICER may either indicate an
ineffective and/or costly comparator or highly effective and/or
inexpensive intervention. Thus, it is important, as we did in this
study, to compare interventions to clinically relevant comparators.
Economic considerations should follow clinical input in the
decision making process [46].
The need for further research is clear. In 2003, the U.S. spent
$21 billion (1.3% of total health care spending) on treatment for
substance use disorders, $4.83 billion (23%) of which was spent by
Medicare and Medicaid [48]. By comparison, Medicare costs for
end stage renal disease (ESRD), which affected over half a million
patients in 2007 [49], were an estimated $20.8 billion in 2007 and
$18.1 billion in 2004 [50] – close to spending on treatment for
substance abuse, which affects a much larger population (about
23.1 million in 2008) [1]. ESRD is very expensive to treat, and the
relatively small group of ESRD patients deserve medically
necessary and appropriate care; in light of the greater population
affected by substance abuse and its broad societal costs ($180.9
billion for drug abuse in 2002) [4], however, it is sensible to direct
additional attention and resources toward identifying and
implementing effective and efficient substance abuse treatments.
Our study has several limitations. First, generalizability is limited
since the study was conducted in St. Louis and targeted drug use
and high-risk sexual behaviors in women. Second, substance abuse
prevention and treatment positively impact housing and employ-
ment sectors [51], costs and frequency of crime [52,53,45], and the
development of the children of users [54], suggesting our results
underestimated the full economic impact of treatment. Third, the
intervention contained components designed for HIV prevention,
rather than exclusively focusing on substance abuse, which reflects
important interactions but may not be as targeted as needed for
policy and treatment purposes. Fourth, the analysis did not include
the incremental differences between 4 months and 12 months,
though that information is derivable from data presented. Fifth,
our study did not measure the longest duration of abstinence for
either cocaine or alcohol. Sixth, the effectiveness outcomes were
measured by self report, and biochemical verification was not
available for the relevant endpoints used in our CEA.
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